« Back
Home /
Eravacycline (dihydrochloride)

Eravacycline (dihydrochloride)

Item no.	HY-16980A-5mg
Manufacturer	MedChem Express
CASRN	1334714-66-7
Amount	5 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Food Safety Antibiotics Neuroscience Neural Lineage Markers By Cell Type Blastoma Carcinoma Cell Biology Cell Status Proliferation Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	98.88
Dry ice	Yes
Citations	[1]Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10.\|[2]Zhao M, et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2017 Jun 27;61(7).\|[3]Xiao XY, et al. Fluorocyclines: a potent, broad spectrum antibacterial agent. J Med Chem. 2012 Jan 26;55(2):597-605.\|[4]Sutcliffe JA, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58.\|[5]Grossman TH, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59(5):2567-71. ACS Infect Dis. 2024 Nov 13.\|Biomaterials. 2024 Sep 11:314:122815.\|Cureus. 2024 Dec 1;16(12):e74917.\|J Antimicrob Chemother. 2021 Feb 11;76(3):653-658.\|Mbio. 2021 May 28;e0103121.\|Microb Pathog. 2020 Dec;149:104502.\|Pharmaceutics. 2021, 13(12), 2085.\|Research Square Preprint. 2022 Feb.\|Ann Lab Med. 2021 May 1;41(3):293-301.\|Antibiotics (Basel). 2022, 11(10), 1298.\|Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19.\|Antimicrob Agents Chemother. 2021 May 18;65(6):e00203-21.\|Antimicrob Agents Chemother. 2024 Jan 30:e0112023.\|Clin Exp Pharmacol Physiol. 2023 Apr 22.\|Diagn Micr Infec Dis. 2020 Nov;98(3):115129.\|Infect Drug Resist. 2023 Apr 17.\|Infect Drug Resist. 2023 Sep 7.\|J Antibiot (Tokyo). 2019 Aug;72(8):600-604. \|J Antibiot (Tokyo). 2022 Jul 27.\|J Antimicrob Chemother. 2021 May 6;dkab141.\|J Clin Microbiol. 2020 Jan 28;58(2):e01603-19.\|Microbiol Spectr. 2022 Dec 8;e0323822.\|Microbiol Spectr. 2023 May 4;e0071823.\|Nat Microbiol. 2023 Mar;8(3):410-423.\|Nat Struct Mol Biol. 2023 Aug 7.\|Virulence. 2022 Dec;13(1):77-88.
Smiles	O=C(NC(C(O)=C1C2=O)=CC(F)=C1C[C@@]3([H])C[C@@]4([H])[C@H](N(C)C)C(O)=C(C(N)=O)C([C@@]4(O)C(O)=C32)=O)CN5CCCC5.[H]Cl.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	TP-434 dihydrochloride,TP-434-046
Shipping Condition	Dry ice
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Bacterial; Beta-lactamase
Shipping Temperature	Dry Ice
Storage Conditions	-80°C, protect from light, stored under nitrogen
Molecular Weight	631.48
Product Description	Eravacycline dihydrochloride (TP-434 dihydrochloride) is a potent and broad-spectrum antibacterial agent.
Manufacturer - Research Area	Infection
Solubility	DMSO: ≥ 50 mg/mL\|H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16980A-5mg-safety-datasheet.pdf